dc.contributor.author | Yönal Hindilerden, İpek | |
dc.contributor.author | Kalayoğlu Beşışık, Sevgi F. | |
dc.contributor.author | Gürses-Koç, Nuray | |
dc.contributor.author | Hindilerden, Fehmi | |
dc.contributor.author | Sargın, Deniz | |
dc.date.accessioned | 10.07.201910:49:13 | |
dc.date.accessioned | 2019-07-10T19:36:35Z | |
dc.date.available | 10.07.201910:49:14 | |
dc.date.available | 2019-07-10T19:36:35Z | |
dc.date.issued | 2017 | en_US |
dc.identifier.citation | Yönal-Hindilerden, İ., Kalayoğlu-Beşışık, S. F., Gürses-Koç, N., Hindilerden, F. ve Sargın, D. (2017). Allogeneic hematopoietic stem cell transplantation for adult acute lymphoblastic leukemia: Results from a single center, 1993-2011. International Journal of Hematology-Oncology and Stem Cell Research, 11(1), 58-62. | en_US |
dc.identifier.issn | 1735-1243 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/1202 | |
dc.description.abstract | Background: For adult ALL patients, the indications and appropriate timing of allogeneic hematopoietic stem cell transplantation (AHSCT) continue to be debated. The primary aim of this single-institution study was to compare the results of our adult ALL patients that had been allografted with those reported in the current literature. Subjects and Methods: This study included 53 consecutive adults with acute lymphoblastic leukemia (ALL) who underwent allogeneic hematopoietic stem cell transplantation (AHSCT) with myeloablative (92%) and reduced-intensity (8%) conditioning between 1993 and 2011. Results: Mean patient age was 27 years (SD: 8.62) and donor age was 33.7 years (SD: 9.47). Fourteen patients were in first remission; 21 in ?2nd remission, 15 in relapse and 3 had primary refractory leukemia. Thirty-four, 15 and 4 patients received busulfan plus cyclophosphamide, cyclophosphamide/total body irradiation and fludarabine-based regimens, respectively. For graft-versus-host disease (GVHD) prophylaxis, cyclosporine plus methotrexate were used. Forty-six donors were related and 7 were unrelated. Thirty patients received granulocyte-colony stimulating factor (G-CSF) mobilized peripheral blood and 23 received bone marrow as stem cell source. Twenty-six patients relapsed at a mean duration of 11.3 months (SD: 19.1). Forty-four patients succumbed to their disease after a mean follow-up of 13.6 months (SD: 19.5). The cause of mortality was relapse (n=24; 54.5%) and transplant-related etiologies (n=20; 45.5%). The estimated five year probabilities of overall survival (OS) and progression-free survival (PFS) were 37% and 12%, respectively. Conclusion: By multivariate analyses, transplantation in first remission was the most important predictor of transplant success. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Tehran University of Medical Sciences (TUMS) | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Acute Lymphoblastic Leukemia | en_US |
dc.subject | Allogeneic Hematopoietic Stem Cell Transplantation | en_US |
dc.subject | Overall Survival | en_US |
dc.subject | Progression-Free Survival | en_US |
dc.title | Allogeneic hematopoietic stem cell transplantation for adult acute lymphoblastic leukemia: Results from a single center, 1993-2011 | en_US |
dc.type | article | en_US |
dc.relation.ispartof | International Journal of Hematology-Oncology and Stem Cell Research | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.identifier.volume | 11 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.startpage | 58 | en_US |
dc.identifier.endpage | 62 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.scopusquality | Q2 | en_US |